A 65-year experience treating acne, including 26 years with oral isotretinoin;Experiência de 65 anos no tratamento da acne e de 26 anos com isotretinoína oral

Anais Brasileiros de Dermatologia

Volumn 83, Issue 4, 2008, Pages 361-367

  Sampaio, Sebastião De Almeida Prado ^a   Bagatin, Edileia ^b,c  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c NONE   (Brazil)

Author keywords

Acne vulgaris; Acne vulgaris prevention e control; Acne vulgaris therapy; Isotretinoin; Isotretinoin therapeutic use

Indexed keywords

ANTIANDROGEN; AZELAIC ACID; AZITHROMYCIN; BENZOYL PEROXIDE; CLINDAMYCIN; CORTICOSTEROID DERIVATIVE; DOXYCYCLINE; ERYTHROMYCIN; ISOTRETINOIN; LYMECYCLINE; MINOCYCLINE; SULFONAMIDE; SULFUR DERIVATIVE; TETRACYCLINE;

ACNE VULGARIS; ALOPECIA; ARTHRALGIA; ATROPHY; CHOLESTEROL BLOOD LEVEL; CONJUNCTIVITIS; CORNEA OPACITY; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG INDICATION; EPISTAXIS; HEADACHE; HUMAN; HYPEROSTOSIS; INFECTION CONTROL; INFECTION PREVENTION; INSOMNIA; MYALGIA; NERVOUSNESS; PSEUDOTUMOR; REVIEW; SIDE EFFECT; TERATOGENICITY; TREATMENT PLANNING; TRIACYLGLYCEROL BLOOD LEVEL; VISUAL DISORDER; XEROPHTHALMIA;

EID: 55249092699     PISSN: 03650596     EISSN: 18064841     Source Type: Journal    
DOI: 10.1590/S0365-05962008000400012     Document Type: Review

References (41)

1. Gollnick H. Current concepts of the pathogenesis of acne. Implications for drug treatment. Drugs. 2003;63:1579-96.
2. Koreck A, Oivarcsi A, Dobozy A, Kemény L. The role of innate immunity in the pathogenesis of acne. Dermatology. 2003;206:96-105.
3. Gollnick H, Cunliffe WJ. Management of acne. A report from a global alliance to improve outcomes in acne. J Am Acad Dermatol. 2003;49:S1-38.
4. Katsambas AD, Stefanaki C, Cunliffe WJ. Guidelines for treating acne. Clin Dermatol. 2004;22:439-44.
5. Strauss JS, Krowchuk DP, Leyden JJ, Lucky AW, Shalita AR, Siegfried EC, et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol. 2007;56:651-63.
6. Baldwin HE. The interaction between acne vulgaris and the psyche. Cutis. 2002;70:133-9.
7. Yazici K, Baz K, Yazici AE, Köktürk A, Tot S, Demirseren D, et al. Disease-specific quality of life is associated with anxiety and depression in patients with acne. J Eur Acad Dermatol Venereol. 2004;18:435-9.
8. Peck GL, Olsen TG, Yoder FW, Strauss JS, Downing DT, Pandya M, et al. Prolonged remission of cystic acne and conglobate acne with 13 cis retinoic acid. N Engl J Med. 1979;300:329-33.
9. Peck GL, Olsen TG, Butkus D, Pandya M, Arnaud-Battandier J, Gross EG, et al. Isotretinoin versus placebo in the treatment of cystic acne. A randomized double-blind study. J Am Acad Dermatol. 1982;6(Pt 2 Suppl):735-45.
10. Jones H, Blanc D, Cunliffe WJ. 13-cis retinoic acid and acne. Lancet. 1980;2:1048-9.
11. Sampaio SAP, Pimentel ERA. Isotretinoína no tratamento da acne vulgar. An Bras Dermatol. 1985; 60:349-52.
12. Barth JH, MacDonald-Hull SP, Mark J, Jones RG, Cunliffe WJ. Isotretinoin therapy for acne vulgaris: a re-evaluation of the need for measurements of plasma lipids and liver function tests. Br J Dermatol. 1993;129:704-7.
13. Lestringant GG, Frossard PM, Agarwal M, Galadari IH. Variations in lipid and lipoprotein levels during isotretinoin treatment for acne vulgaris with special emphasis on HDL-cholesterol. Int J Dermatol. 1997;36:859-62.
14. Altman RS, Altman LJ, Altman JS. A proposed set of new guidelines for routine blood tests during isotretinoin therapy for acne vulgaris. Dermatology. 2002;204:232-5.
15. Layton AM, Knaggs H, Taylor J, Cunliffe WJ. Isotretinoin for acne vulgaris - 10 years later: a safe and successful treatment. Br J Dermatol. 1993;129:292-6.
16. Cunliffe WJ, van de Kerkhof PCM, Caputo R, Cavicchini S, Cooper A, Fyrand OL, et al. Roaccutane treatment guidelines: results of an international survey. Dermatology. 1997; 194:351-7.
17. Ellis CN, Krach KJ. Uses and complications of isotretinoin therapy. J Am Acad Dermatol. 2001;45:S150-7.
18. McLane J. Analysis of common side effects of isotretinoin. J Am Acad Dermatol. 2001; 45:S188-94.
19. Herane MIH. Isotretinoína oral: efectos adversos. Rev Chil Dermatol. 2002;18:71-6.
20. Wiegand UW, Chou RC. Pharmacokinetics of oral isotretinoin. J Am Acad Dermatol. 1998; 39(Pt 3):S8-12.
21. Nau H. Teratogenicity of isotretinoin revisited: species variation and the role of all-trans-retinoic acid. J Am Acad Dermatol. 2001;45:S183-7.
22. Strahan JE, Raimer S. Isotretinoin and the controversy of psychiatric adverse effects. In J Dermatol. 2006;45:789-99.
23. Jacobs DG, Deutsch NL, Brewer M. Suicide, depression, and isotretinoin: is there a causal link? J Am Acad Dermatol. 2001;45:S168-75.
24. Wysowski DK, Pitts M, Beitz J. An analysis of reports of depression and suicide in patients treated with isotretinoin. J Am Acad Dermatol. 2001;45:515-9.
25. Ng CH, Tam MM, Celi E, Tate B, Schweitzer I. Propsective study of depressive symptoms and quality of life in acne vulgaris patients treated with isotretinoin compared to antibiotic and topical therapy. Austr J Dermatol. 2002;43:262-8.
26. Hersom K, Neary MP, Levaux HP, Klaskala W, Strauss JS. Isotretinoin and antidepressant pharmacotherapy: a prescription sequence symmetry analysis. J Am Acad Dermatol. 2003;49:424-32.
27. Jick SS, Kermers M, Vasilakis-Scamarazza C. Isotretinoin use and risk of depression, psychotic symptoms, suicide and attempted suicide. Arch Dermatol. 2000;136:1231-6.
28. Kellett SC, Gawkrodger DJ. The psychological and emotional impact of acne and the effect of treatment with isotretinoin. Br J Dermatol. 1999;140:273-82.
29. Chia CY, Lane W, Chibnall J, Allen A, Siegfried E. Isotretinoin therapy and mood changes in adolescents with moderate to severe acne: a cohort study. Arch Dermatol. 2005; 141:557-60.
30. Yarak S, Bagatin E, Hassun KM, Parada MOB, Talarico Filho S. Hiperandrogenismo Pele: Síndrome do Ovário Policístico e Resistência Periférica à Insulina. An Bras Dermatol. 2005;80:395-410.
31. Lehucher-Ceyrac D, Chaspoux C, Weber MJ, Morel P, Vexiau P. Acné, hyperandrogénie et résistance à l'iotrétinoïne orale. 23 cas. Implications thérapeutiques. Ann Dermatol Venereol. 1997;124:692-5.
32. Yildiz BO. Diagnosis of hyperandrogenism: clinical criteria. Best Pract Res Clin Endocrinol Metab. 2006;20:167-76.
33. Moghetti P, Toscano V. Treatment of hirsutism and acne in hyperandrogenism. Best Pract Res Clin Endocrinol Metab. 2006; 20:221-34.
34. Sanchez QE. Metabolitos de la isotretinoína principales responsables de sus efectos terapéuticos y adversos. Rev Chil Dermatol. 2003;19:14-23.
35. Mandekou-Lefaki I, Delli F, Teknetziz A, Euthimiadou R, Karakatsanis G. Low-dose schema of isotretinoin in acne vulgaris. Int J Clin Pharm Res. 2003; 23:41-6.
36. Amichai B, Shemer A, Grunwald MH. Low-dose isotretinoin in the treatment of acne vulgaris. J Am Acad Dermatol. 2006; 54:644-6.
37. Katsambas AD. Why and when the treatment of acne fails. What to do. Dermatology. 1998;196:158-61.
38. Lehucher-Ceyrac D, de La Salmonière P, Chastang Cl, Morel P. Predictive factors for failure of isotretinoin treatment in acne patients : results from a cohort of 237 patients. Dermatology. 1999;198:278-83.
39. Quéreux G, Volteau C, N'Guyen JM, Dréno B. Prospective study of risk factors of relapse after treatment of acne with oral isotretinoin. Dermatology. 2006;212:168-76.
40. Wysowski DK.Use of isotretinoin (Accutane) in the United States: rapid increase from 1992 - 2000. J Am Acad Dermatol. 2002;46:505-9.
41. Cunliffe WJ, Baron SE, Coulson IH. A clinical and therapeutic study of 29 patients with infantile acne. Br J Dermatol. 2001;145:463-6.